HCMV Breakthrough Infections During Letermovir Prophylaxis

NARecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

March 31, 2026

Conditions
Cytomegalovirus InfectionsCytomegalovirus ViremiaHematopoietic Stem Cell Transplantation
Interventions
DIAGNOSTIC_TEST

Determination of HCMV DNA in plasma after DNAse digestion.

Plasma will be tested after DNAse digestion for quantification of virion-associated HCMV DNA (defined as true breakthrough HCMV productive infection).

DIAGNOSTIC_TEST

Determination of HCMV DNA in blood or plasma.

HCMV DNA will be determined in blood or plasma without DNAse digestion, as per current clinical practice.

Trial Locations (8)

27100

RECRUITING

Fondazione IRCCS Policlinico San Matteo, Pavia

Unknown

RECRUITING

ASST-Spedali Civili, Brescia

NOT_YET_RECRUITING

ASST-Ospedale Papa Giovanni XXIII, Bergamo

NOT_YET_RECRUITING

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna

NOT_YET_RECRUITING

ASST Grande Ospedale Metropolitano Niguarda, Milan

NOT_YET_RECRUITING

"Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli", Reggio Calabria

NOT_YET_RECRUITING

AOU Policlinico Umberto I, Roma

NOT_YET_RECRUITING

Policlinico Universitario Agostino Gemelli, Roma

All Listed Sponsors
collaborator

Ministero della Salute, Italy

OTHER

lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER